Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Q1 2025 Earnings Presentation
20 slides from Vivoryon Therapeutics's earnings presentation, Jun 17, 2025
Slide 1: Q1 Financial Results Webcast and Conference Call
Q1 Financial Results Webcast and Conference Call June 17, 2025 Vivoryon Therapeutics N.V.
Slide 2: Agenda
Agenda Recent Key Achievements Q&A Julia Neugebauer, PhD Chief Operating Officer Frank Weber, MD Chief Executive Officer Anne Doering, CFA Chief Financial Officer Varoglutamstat for Kidney Disease Frank Weber, MD Julia Neugebauer, PhD Chief Executive Officer Chief Operating Officer Michael Schaeffer
Slide 3: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 4: Recent key achievements
Recent key achievements ◆ Robust data from two independent Phase 2 studies showing improvement in pre-specified kidney measure (eGFR) ◆ Meta-analysis data presented at ERA 2025 further confirming highly consistent & clinically meaningful effect ◆ Continued progress in strategy to develop varoglutams
Slide 5: Varoglutamstat has the potential to transform kidney health outcomes
Varoglutamstat has the potential to transform kidney health outcomes Frank Weber, CEO
Slide 6: Two independent randomized Phase 2 studies evaluated kidney function
Vivoryon has evaluated varoglutamstat’s effect on kidney function in two independent randomized double-blind placebo-controlled Phase 2 studies Strong proof of principle data in over 360 patients treated for up VIVIAD Phase 2b to 2 years provide basis for development of varoglutamstat in Europe, n=2
Slide 7: ERA 2025: Meta-analysis from two independent Phase 2 studies
ERA 2025: Meta-analysis from two independent Phase 2 studies presented to scientific & medical community in June 2025 Next step: Phase 2b in DKD Stage 3b/4 target population1 Weber et al., ERA 2025, abstract no. 1174; 1subject to funding / partnership. 7 © Vivoryon Therapeutics N.V.
Slide 8: Varoglutamstat sets itself apart in the kidney space
Varoglutamstat’s ability to stabilize and partially recover kidney function sets it apart in the kidney space and supports its potential to transform disease outcomes Oral Preserves kidney function improving eGFR New MoA Varoglutamstat Stabilizing or Alpine (acq. Synergistic with SoC Larger
Slide 9: eGFR slope analysis is a valid surrogate endpoint in CKD trials
eGFR slope analysis is a valid surrogate endpoint in clinical trials in CKD Key statements on relevance of eGFR in clinical trials from scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency “We conclude
Slide 10: Unique effect of varoglutamstat on eGFR slope
Unique effect of varoglutamstat on eGFR slope – a key regulatory endpoint Currently available medicines only slow disease progression in DKD SGLT2 GLP-1 MRA QPCT/L Delta eGFR slope (mL/min/1.73m2/year) 6 60 Albuminuria reduction (%) 5 50 4 40 3 30 2 20 1 10 0 0 1 2 3 4 Dapagliflozin Canagliflozin Se
Slide 11: eGFR slope analysis and simulations highlight feasibility of Phase 3 program
eGFR slope analysis and simulations based on available Phase 2 results highlight feasibility of a future Phase 3 program for varoglutamstat Pooled slope analysis data from Phase 2 VIVIAD / VIVA-MIND studies in patients with diabetes: Varoglutamstat 600mg BID, n=46 ; slope + 1.68, Placebo, n=48, slop
Slide 12: Combinations with SGLT-2 inhibitors are the next wave of DKD treatment
Combinations with SGLT-2 inhibitors are the next wave of DKD treatment SGLT2i are a foundational part of combination therapies CONFIDENCE1 (empagliflozin + finerenone) ns-MRA 52% reduction of UACR vs. baseline SGLT2i Finerenone after 6 months ns-MRA MIRACLE2 (dapagliflozin + balcirenone) 48% reducti
Slide 13: Pre-clinical data show synergistic effects with standard of care
Pre-clinical data show impressive synergistic effects of varoglutamstat with standard of care, substantially de-risking the planned DKD / CKD clinical program Inflammation (CD11c) ◆ SGLT-2 inhibitors (SGLT2i) are now SoC for patients with CKD 1 ◆ Strong synergistic effect observed when varoglutamsta
Slide 14: New composition of matter patent granted in U.S.
New composition of matter patent recently granted in U.S provides exclusivity for varoglutamstat up until at least 2044, with potential for further extensions IP-strategy: recent highlights & updates PTE option NEW HCl polymorph, granted 2044 max. 2049 Composition of matter 2045 max. 2050 Broad, all
Slide 15: Varoglutamstat: potential convenient new oral therapy for kidney disease
Varoglutamstat: Potential to become a convenient new oral therapy to transform the treatment of kidney disease Medical Need Opportunity Therapies that can stabilize Varoglutamstat is a first-in-class single agent oral compound that has or improve kidney function been shown to stabilize and partially
Slide 16: Q1 2025 Financial Results & Outlook
Q1 2025 Financial Results & Outlook Anne Doering, CFO
Slide 17: Key financial figures
Key financial figures In €k Three months ended Three months ended Mar. 31, 2025 Mar. 31, 2024 Revenue 0 0 Research & Development expenses (1,165) (7,425) General & Administrative expenses (1,330) (2,084) Net loss for the period (2,459) (9,329) In €k Mar. 31, 2025 Dec. 31, 2024 Cash & cash equivalent
Slide 18: Poised to improve kidney health outcomes with varoglutamstat
Poised to improve kidney health outcomes with varoglutamstat’s breakthrough clinical study results Unique oral asset with Compelling Phase 2 MoA targeting results replicated in two inflammation & fibrosis independent studies1 Aiming to transform the treatment of kidney disease Actionable development
Slide 19: Q&A
Q &A
Slide 20: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Q1 2025 Earnings Presentation on 6ix